A Phase 4 interventional study of Fluoxetine and Cognitive-behavioral therapy in Depression and HIV, sponsored by University of Ibadan. Not yet recruiting at 1 site in Nigeria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-08.
Sponsored by University of Ibadan · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing fluoxetine in Depression — 9 open to participants now, 10 under way, 1 of them phase 3. Fluoxetine · Depression.
Among the 43 studies testing fluoxetine in Depression, this one is the 16th largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2025, is one of 9 in phase 4, and was the 40th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →9 of the 43 studies testing fluoxetine in Depression are open now, in 7 countries. Recruiting first, the newest first:
University of Oxford · Sites in United Kingdom
Ages 18–24 · Healthy volunteers
University of Bern · Sites in Zimbabwe
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Poznan University of Medical Sciences · Sites in Poland
Ages 12+
Federal University of Latin American Integration · Sites in Brazil
Ages 25–65 · Healthy volunteers
By country, each count listing its studies:
Fluoxetine: first FDA approval 1987 (SARAFEM). What it is approved for, and how studies give it, is on its page →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 9 · Phase 4 9
First in 1995; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 168 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 97 across the 42 interventional studies. Of the 30 that completed or were terminated, 13 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 43 have an industry lead sponsor. The 10 most frequent:
University of Ibadan is the lead sponsor of 21 studies on the registry; 4 are open to participants now.
University of Ibadan has 2 studies filed under Depression — fewer than ten, so there is no comparison to draw.
6 of the studies testing fluoxetine in Depression that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424781University of OxfordFluoxetine on Emotional Experience (FLEX) Study | 2026-12-31 |
| NCT05814640First Affiliated Hospital of Chongqing Medical UniversitySequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) | 2026-12-31 |
| NCT05976347Wake Forest University Health SciencesIdentifying and Treating Depression in the Orthopaedic Trauma Population | 2027-05 |
| NCT07456501University of OxfordFluoxetine and Understanding Social Experiences | 2027-07-20 |
| NCT07110831University of IbadanDisposition Kinetics of Dolutegravir Among People Living With HIV With Major Depression in Nigeria | 2027-09-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 43 studies testing fluoxetine in Depression, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to find out the usefulness and well-being of people when drugs for treating depression (fluoxetine) and HIV (dolutegravir) are used together. It will also learn about how safe it is to take fluoxetine and dolutegravir together by the people living with HIV (PLWH).
The main questions it aims to answer are:
Participants on anti-HIV dolutegravir having depression will:
Depression is the most mental health disorder disorder among people living with HIV (PLWH) and is predictive of increased HIV-related morbidity and mortality. Treatment of depression in the setting of HIV is challenging as adding antidepressants in combination with combination antiretroviral therapy (cART) increases the pill burden and the potential for drug interactions. Studies have reported HIV medication complexity in patients comorbid with major depression to affect cART adherence. Optimal depression control among PLWH predicts and improves cART adherence and treatment outcomes.
Expert consensus is that selective serotonin-reuptake inhibitors (SSRIs) should be the first-line treatment for depression among PLWH. However, it is unclear whether SSRI therapy is effective in PLWH in low-middle-income countries (LMICs). There is an underrepresentation of LMICs in clinical studies involving PLWH and major depression despite the higher burden of PLWH and depression in LMICs than the high-income countries (HICs).
Fluoxetine is the preferred SSRI and most used for the treatment of depression in LMICs and is approved by their drug regulatory authorities. Fluoxetine is the most evaluated SSRI among PLWH with major depression but with different response rates among various ethnic groups reported. Furthermore, while fluoxetine was the most common SSRI used among the available clinical studies among PLWH, the studies did not report the clinical outcomes related to HIV care and cART.
Dolutegravir (DTG), an integrase strand transfer inhibitor, is the preferred and recommended first-line antiretroviral agent for adults and adolescents with HIV in LMICs. DTG is highly effective in suppressing HIV in both treatment-naive and experienced PLWHs, in addition to a low adverse effect profile and a high genetic barrier to developing drug resistance.
The cytochrome P450 (CYP) enzyme system metabolises fluoxetine, while the major enzyme that metabolises DTG is UGT1A1, with some contribution from CYP3A4/5. Fluoxetine and its major metabolite, norfluoxetine, may inhibit multiple enzymes involved in DTG metabolism, especially during chronic administration. A minor interaction via a membrane transporter mechanism may also be more pronounced with chronic use through the inhibition of the P-gp-mediated transport of DTG by fluoxetine. Patients on DTG report neuropsychiatric adverse events, and there is a relationship between plasma DTG trough concentration, neuropsychiatric adverse events, and UGT1A1 single nucleotide polymorphisms (SNPs). Thus, increases in DTG trough concentrations resulting from drug interaction are a potentially important concern.
Understanding potential drug interactions when fluoxetine and DGT-based cART are co-administered together will assist in optimising the dosing regimen, reducing adverse effects, and improving treatment outcomes among PLWH with major depression. To be able to recommend DTG and fluoxetine concomitant use, a prospective study involving PLWH with major depression is proposed. This study will address key knowledge gaps in drug interactions between fluoxetine and DTG among PLWH with major depression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with a HAM-D score greater than 13 (moderate, moderately severe, and severe depression) will be recruited and allocated to the intervention group. The psychiatrist will commence the participants on fluoxetine (starting with 20mg daily). The psychiatrist will determine the dose of fluoxetine, and the dose may be adjusted during follow-up. Participants will receive Cognitive Behavioural Therapy (CBT) delivered by a Clinical psychologist in addition to fluoxetine as part of the standard routine care.
Drug: Fluoxetine · Behavioral: Cognitive-behavioral therapy
Participants with HAM-D score between 8 and 13 (mild depression) will be recruited and allocated to the control group. They will receive only Cognitive Behavioural Therapy (CBT) as per standard routine care.
Behavioral: Cognitive-behavioral therapy
Participants in the intervention arm will receive oral fluoxetine capsules starting with 20mg daily for 12 weeks. The dose of the fluoxetine may be adjusted during follow-up by titrating the dose against the participants' response..
Also known as: Prozac, Fluoxetine hydrochloride, Rapiflux, Sarafem, Selfemra, Fluoxetin, Lilly-110140, N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
Participants with HAM-D score of between 8 and 13 (mild depression) will receive sessions of Cognitive Behavioural Therapy (CBT) as per standard routine care. Participants in the intervention arm will also receive sessions of CBT as per standard routine care.
Also known as: Psychotherapy, Cognitive Behavioral Therapy, Cognitive Behavioural Therapy, Cognitive Psychotherapy, Cognitive Therapy, CBT
Mean change in the Hamilton Depression Rating Scale (HAM-D) scores from baseline to 12 weeks
The total HAM-D scores provide an indication of depression and, over time, a guide to evaluate response and recovery. The higher the HAM-D scores, the higher the severity of depression. HAM-D is graded as follows None 0-7 Mild 8-16 Moderate 17-23 Severe ≥ 24
Time frame: Baseline to the end of treatment at 12 weeks
Mean changes in the AUC of dolutegravir
The effect of chronic administration of fluoxetine on the steady-state pharmacokinetics of dolutegravir and by intrasubject comparison in the participants. This will be assessed with mean changes in the Area under the plasma concentration-time curve (AUC) before and after the administration of fluoxetine.
Time frame: Week 2 to the end of treatment at 12 weeks
Mean changes in the Cmax of doultegravir
The effect of chronic administration of dolutegravir on the steady-state pharmacokinetics of fluoxetine by intrasubject comparison in the participants. This will be assessed with mean changes in the Maximum plasma concentration (Cmax) before and after the administration of fluoxetine.
Time frame: Week 2 to the end of treatment at 12 weeks
Mean changes in the Cmin of dolutegravir
Description: The effect of chronic administration of fluoxetine on the steady-state pharmacokinetics of dolutegravir and by intrasubject comparison in the participants. This will be assessed with mean changes in the Minimum plasma concentration(Cmin) before and after the administration of fluoxetine.
Time frame: Week 2 to the end of treatment at 12 weeks
Mean changes in the AUC of fluoxetine
The effect of chronic administration of dolutegravir on the steady-state pharmacokinetics of fluoxetine by intrasubject comparison in the participants. This will be assessed with mean changes in the Area under the plasma concentration-time curve (AUC) before and after the administration of fluoxetine.
Time frame: Week 2 to the end of treatment at 12 weeks
Mean changes in the Cmax of fluoxetine
The effect of chronic administration of dolutegravir on the steady-state pharmacokinetics of fluoxetine by intrasubject comparison in the participants. This will be assessed with mean changes in the Maximum plasma concentration (Cmax) before and after the administration of fluoxetine
Time frame: Week 2 to the end of treatment at 12 weeks
Mean changes in the Cmin of fluoxetine
The effect of chronic administration of dolutegravir on the steady-state pharmacokinetics of fluoxetine by intrasubject comparison in the participants. This will be assessed with mean changes in the Minimum plasma concentration (Cmin) before and after the administration of fluoxetine.
Time frame: Week 2 to the end of treatment at 12 weeks
Proportion of participants reporting grade 3 or 4 Adverse Events as Assessed by the DAIDS AE Grading Table Corrected Version 2.1
The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected version 2.1 consists of parameters, or Adverse Events (AEs), with severity grading guidance that is used in DAIDS clinical trials for safety data reporting to maintain accuracy and consistency in the evaluation of AEs. The DAIDS AEs is graded as follows: Grade 1 mild event, Grade 2 moderate event, Grade 3 severe event, Grade 4 potentially life-threatening event and Grade 5 death
Time frame: Baseline to weeks 2, 4, 8, and 12
Proportion of participants with depression remission at week 12
To determine the proportion of participants with depression remission at week 12 This will be measured as the proportion of subjects with HAM-D score of less than 8 (HAM-D\<8)
Time frame: Baseline to the end of treatment at 12 weeks
Proportion of participants with a change of greater than or equal to (≥) 50% in the depression score from baseline to weeks 6, 8, and 12
To determine the proportion of participants with a change of greater than or equal to (≥) 50% in the HAM-D scores from baseline to weeks 6, 8 and 12
Time frame: Baseline to weeks 6, 8 and 12
Proportion of participants that drop out (study dropouts) during the study
To determine that proportion of participants that drop out (study dropouts) from baseline till the end of study at week 12.
Time frame: Baseline to weeks 2, 4, 6, 8, and 12
Proportion of participants with viral suppression (≤ 50 copies/mL)
To determine the proportion of participants with HIV viral suppression ( viral load ≤ 50 copies/mL) at the end of study at week 12
Time frame: Baseline to the end of study at week 12
Mean increase in the CD4 count of participants
To determine the mean changes in the CD4 counts of participants from baseline to the end of study at week 12
Time frame: Baseline to the end of study at week 12
AUC of fluoxetine and norfluoxetine
To determine the Area under the plasma concentration-time curve (AUC) of fluoxetine and norfluoxetine using intensive and sparse pharmacokinetic sampling at steady state.
Time frame: Weeks 2, 6,10 and 12
Cmax of fluoxetine and norfluoxetine
To determine the Maximum plasma concentration (Cmax) of fluoxetine and norfluoxetine using intensive and sparse pharmacokinetic sampling at steady state.
Time frame: Weeks 2, 6,10 and 12
Cmin of fluoxetine and norfluoxetine
To determine the Area Minimum plasma concentration (Cmin) of fluoxetine and norfluoxetine using intensive and sparse pharmacokinetic sampling at steady state.
Time frame: Weeks 2, 6,10 and 12
Tmax of fluoxetine and norfluoxetine
To determine the time to maximum observed plasma concentration (Tmax) of fluoxetine and norfluoxetine using intensive and sparse pharmacokinetic sampling at steady state.
Time frame: Weeks 2, 6,10 and 12
Half-life (t1/2) of fluoxetine and norfluoxetine
To determine the elimination half-life (t1/2) of fluoxetine and norfluoxetine using intensive and sparse pharmacokinetic sampling at steady state.
Time frame: Weeks 2, 6,10 and 12
Apparent Total Body Clearance (CL/F) of fluoxetine and norfluoxetine
To determine the Apparent Total Body Clearance (CL/F) of fluoxetine and norfluoxetine using intensive and sparse pharmacokinetic sampling at steady state.
Time frame: Weeks 2, 6,10 and 12
Apparent Volume of Distribution (Vd/F) of of fluoxetine and norfluoxetine
To determine the Apparent Volume of Distribution (Vd/F) of fluoxetine and norfluoxetine using intensive and sparse pharmacokinetic sampling at steady state.
Time frame: Weeks 2, 6,10 and 12
AUC of dolutegravir
To determine the Area under the plasma concentration-time curve (AUC) of dolutegravir using intensive and sparse pharmacokinetic sampling at steady state.
Time frame: Weeks 2, 6,10 and 12
Cmax of dolutegravir
To determine the Maximum plasma concentration (Cmax) of dolutegravir using intensive and sparse pharmacokinetic sampling at steady state.
Time frame: Weeks 2, 6,10 and 12
Cmin of dolutegravir
To determine the Minimum plasma concentration (Cmin) of dolutegravir using intensive and sparse pharmacokinetic sampling at steady state.
Time frame: Weeks 2, 6,10 and 12
Tmax of dolutegravir
To determine the Time to maximum observed plasma concentration (Tmax) of dolutegravir using intensive and sparse pharmacokinetic sampling at steady state.
Time frame: Weeks 2, 6,10 and 12
Half-Life (t1/2) of dolutegravir
To determine the elimination Half-Life (t1/2) of dolutegravir using intensive and sparse pharmacokinetic sampling at steady state.
Time frame: Weeks 2, 6,10 and 12
Apparent Total Body Clearance (CL/F) of dolutegravir
To determine the Apparent Total Body Clearance (CL/F) of dolutegravir using intensive and sparse pharmacokinetic sampling at steady state.
Time frame: Weeks 2, 6,10 and 12
Apparent Volume of Distribution (Vd/F) of dolutegravir
To determine the Apparent Volume of Distribution (Vd/F) of dolutegravir using intensive and sparse pharmacokinetic sampling at steady state.
Time frame: Weeks 2, 6,10 and 12
Plan to share: Yes — De-identified participant data will be shared post-trial as per NIH and the University of Ibadan's policies.
Supporting information: Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: After the study
Access criteria: Researchers can access individual participant data by submitting a proposal and data sharing agreement to the principal investigator.
Start is estimated for Aug 2025; primary completion for Sep 2027, 25 months later.
Of 110 non-industry phase 4 interventional studies under Depression, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 25 months is below that.
Counting every sponsor, half of 119 studies reached it within 32 months; a quarter within 17 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluoxetine
University of Ibadan